Tag: rare biomarkers specimen collection and stabilization market growth

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Value Of The Rare Biomarkers Specimen Collection And Stabilization Market Projected To Expand During 2026–2030?

The market size for rare biomarkers specimen collection and stabilization has seen considerable expansion in recent years. This market is projected to increase from $35.29 billion in 2025 to $38.94 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.3%. The growth observed in previous periods is attributable to factors such as the rise in molecular diagnostics research, the broadening of oncology biomarker studies, the widespread availability of plasma-based testing methods, heightened clinical trial activity, and the increasing adoption of biobanking practices.

The rare biomarkers specimen collection and stabilization market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach a valuation of $55.35 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.2%. This anticipated growth is driven by several factors including the rising embrace of precision diagnostics, a heightened need for early disease identification, the broadening scope of genomic and transcriptomic testing, increased financial commitments to biomarker-guided drug discovery, and the expanding incorporation of AI in biomarker assessment. Key developments expected during this period involve a greater uptake of liquid biopsy collection methods, the expanded utilization of sophisticated stabilization reagents, an escalating requirement for preserving high-sensitivity biomarkers, the widening application of non-invasive diagnostics, and a sharpened emphasis on the integrity and traceability of samples.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

Which Core Factors Are Supporting The Expansion Of The Rare Biomarkers Specimen Collection And Stabilization Market?

The rising incidence of cancer is anticipated to drive the expansion of the rare biomarker specimen collection and stabilization market moving forward. Cancer encompasses a diverse group of diseases characterized by the uncontrolled division and spread of abnormal cells throughout the body. The escalation in cancer cases is attributed to elements such as environmental exposures, lifestyle choices including smoking and poor dietary habits, and genetic vulnerabilities, all of which heighten the demand for precise diagnostic and monitoring tools. In oncology, rare biomarker specimen collection and stabilization are vital for ensuring the accurate preservation of blood- and tissue-based biomarkers, which are critical for early detection, molecular profiling, and guiding therapy selection. As an illustration, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, forecasted over 35 million new cancer cases by 2050, marking a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the growing prevalence of cancer is a key factor propelling the growth of the rare biomarker specimen collection and stabilization market.

What Segment Categories Are Evaluated In The Rare Biomarkers Specimen Collection And Stabilization Market Study?

The rare biomarkers specimen collection and stabilization market covered in this report is segmented –

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles

2) By Specimen: Serum Or Plasma, Other Specimens

3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications

4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA

2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow

3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

What Trends Are Affecting The Growth Of The Rare Biomarkers Specimen Collection And Stabilization Market?

Major companies operating in the rapid diagnostics market are prioritizing advancements and innovation, such as rapid diagnostic testing tools, to enhance diagnostic accuracy, reduce turnaround times, and improve patient outcomes in point-of-care settings. Rapid diagnostic testing tools are medical devices designed to quickly detect the presence of specific diseases or conditions, typically providing results within minutes at the point of care. For instance, in May 2025, SEKISUI Diagnostics, a US-based medical diagnostics manufacturer, launched the OSOM RSV Test, a rapid diagnostic tool for detecting respiratory syncytial virus (RSV). This test is intended for use in professional healthcare settings and delivers results in just 15 minutes. It employs a rapid immunochromatographic assay to qualitatively detect RSV nucleoprotein antigen. The test uses anterior nasal swab specimens collected from patients showing symptoms of respiratory infection, and its quick turnaround time supports timely and effective clinical decision-making.

Who Are The Companies Shaping The Rare Biomarkers Specimen Collection And Stabilization Market Landscape?

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Access The Complete Rare Biomarkers Specimen Collection And Stabilization Market Report:

https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Which Area Represents The Largest Portion Of The Rare Biomarkers Specimen Collection And Stabilization Market?

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Rare Biomarkers Specimen Collection And Stabilization Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2026, By The Business Research Company

Blood Transfusion Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Hematology Diagnostic Devices And Equipment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-diagnostic-devices-and-equipment-global-market-report

Immunochemistry Diagnostic Devices And Equipment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Rare Biomarkers Specimen Collection And Stabilization Market From 2026 To 2030?

The rare biomarkers specimen collection and stabilization market size has seen rapid growth in recent years. It is anticipated to expand from $35.29 billion in 2025 to $38.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. The historical period’s growth can be attributed to an increase in molecular diagnostics research, the expansion of oncology biomarker studies, the availability of plasma-based testing methods, heightened clinical trial activity, and the growing implementation of biobanking practices.

The rare biomarkers specimen collection and stabilization market is poised for robust expansion over the coming years. By 2030, its valuation is projected to reach $55.35 billion, demonstrating a compound annual growth rate (CAGR) of 9.2%. This anticipated growth during the forecast period stems from factors such as the heightened embrace of precision diagnostics, an escalating need for timely disease identification, the broader application of genomic and transcriptomic testing, increasing capital expenditure in drug development guided by biomarkers, and the greater incorporation of AI into biomarker analysis. Key developments expected in the forecast period encompass the wider acceptance of liquid biopsy collection methods, increased deployment of sophisticated stabilization reagents, a heightened necessity for preserving high-sensitivity biomarkers, the broadening scope of non-invasive diagnostic uses, and a reinforced emphasis on the integrity and traceability of samples.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

Which Drivers Are Supporting The Rare Biomarkers Specimen Collection And Stabilization Market Growth?

The rising incidence of cancer is anticipated to fuel the expansion of the rare biomarker specimen collection and stabilization market in the future. Cancer encompasses a diverse range of illnesses marked by the uncontrolled multiplication and dissemination of atypical cells. This uptick in cancer cases stems from elements like environmental factors, lifestyle choices such as tobacco use and unhealthy eating, and inherited predispositions, collectively intensifying the demand for accurate diagnostic and monitoring instruments. The collection and stabilization of rare biomarker specimens are crucial for ensuring the precise preservation of blood- and tissue-derived biomarkers, which are essential for early diagnosis, molecular analysis, and treatment selection in oncology. A notable example comes from February 2024, when the World Health Organization, an intergovernmental entity based in Switzerland, forecast over 35 million new cancer diagnoses by 2050, marking a 77% rise from the approximately 20 million cases recorded in 2022. Consequently, the escalating incidence of cancer is propelling the growth of the rare biomarker specimen collection and stabilization market.

How Is Segmentation Applied In The Rare Biomarkers Specimen Collection And Stabilization Market Segment Analysis?

The rare biomarkers specimen collection and stabilization market covered in this report is segmented –

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles

2) By Specimen: Serum Or Plasma, Other Specimens

3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications

4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA

2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow

3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

Which Trends Are Expected To Impact The Rare Biomarkers Specimen Collection And Stabilization Market?

Leading companies in the rare biomarkers specimen collection and stabilization market are prioritizing the development of advanced solutions, such as automated plasma and cell sample processing, to maintain biomarker integrity and enable high-throughput multiomics. Automated pre-analytical platforms refer to technologies that standardize the processing of blood samples like plasma separation, cell fixation, and slide preparation directly at the point of collection, ensuring consistent specimen quality without manual handling or specialized tubes. For instance, in April 2024, Tethis S.p.A., an Italy-based biotechnology company, announced the enrollment of its first two patients in a clinical study for its See.d platform. This platform automates standardized plasma and cell sample preparation for multiomic liquid biopsy, including the fixation of rare circulating tumor and immune cells on nanocoated SmartBioSurface slides. Designed to maximize sample integrity and facilitate seamless analysis of cell-free DNA and circulating tumor cells from a single draw, the platform supports the entire workflow of rare biomarker specimen collection and stabilization.

Who Are The Companies Participating In The Rare Biomarkers Specimen Collection And Stabilization Market Environment?

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Get The Full Rare Biomarkers Specimen Collection And Stabilization Market Report:

https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Which Region Is The Leading Market For The Rare Biomarkers Specimen Collection And Stabilization Market?

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Rare Biomarkers Specimen Collection And Stabilization Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2026, By The Business Research Company

Blood Transfusion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Hematology Diagnostic Devices And Equipment Market Report

https://www.thebusinessresearchcompany.com/report/hematology-diagnostic-devices-and-equipment-global-market-report

Immunochemistry Diagnostic Devices And Equipment Market Report

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Rare Biomarkers Specimen Collection And Stabilization Market During The Forecast Period 2026–2030?

The rare biomarkers specimen collection and stabilization market size has experienced rapid growth in recent years. It is anticipated to increase from $35.29 billion in 2025 to $38.94 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. The historical expansion of this market is attributable to developments such as the growth in molecular diagnostics research, the expansion of oncology biomarker studies, the availability of plasma-based testing methods, increasing clinical trial activity, and the rising use of biobanking practices.

The rare biomarkers specimen collection and stabilization market is projected to experience substantial expansion in the coming years, anticipated to reach a valuation of $55.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. This growth during the forecast period is primarily attributable to factors such as the wider uptake of precision diagnostics, a surging need for early disease identification, the expansion of genomic and transcriptomic testing methodologies, increasing financial commitments to biomarker-driven drug development, and the growing incorporation of AI into biomarker analysis. Furthermore, key trends shaping the market over this period encompass the increasing integration of liquid biopsy collection methods, the expanded utilization of sophisticated stabilization reagents, a heightened requirement for preserving high-sensitivity biomarkers, the broadening scope of non-invasive diagnostic applications, and a reinforced emphasis on the integrity and traceability of samples.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

Which Major Factors Are Driving The Expansion Of The Rare Biomarkers Specimen Collection And Stabilization Market?

The market for rare biomarker specimen collection and stabilization is anticipated to expand due to the rising occurrence of cancer. Cancer encompasses a wide range of illnesses marked by the unrestrained proliferation and dissemination of abnormal cells. This surge in cancer cases stems from elements like environmental factors, lifestyle choices such as smoking and an unhealthy diet, and inherent genetic predispositions, collectively creating a greater demand for accurate diagnostic and monitoring instruments. The crucial function of rare biomarker specimen collection and stabilization involves ensuring the precise preservation of blood- and tissue-derived biomarkers, essential for initial diagnosis, molecular characterization, and choosing appropriate therapies in cancer treatment. For example, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, forecast more than 35 million new cancer cases by 2050. This figure signifies a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing incidence of cancer is a key factor propelling the expansion of the rare biomarker specimen collection and stabilization market.

What Market Segments Are Evaluated Within The Rare Biomarkers Specimen Collection And Stabilization Market?

The rare biomarkers specimen collection and stabilization market covered in this report is segmented –

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles

2) By Specimen: Serum Or Plasma, Other Specimens

3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications

4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA

2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow

3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

What Trends Are Affecting The Expansion Of The Rare Biomarkers Specimen Collection And Stabilization Market?

Companies operating in the rare biomarkers specimen collection and stabilization market are increasingly concentrating on developing advanced solutions, such as automated plasma and cell sample preparation, to maintain biomarker integrity and enable high-throughput multiomics. These automated pre-analytical platforms refer to technologies that standardize the processing of blood samples, including plasma separation, cell fixation, and slide preparation, directly at the point of collection, ensuring consistent specimen quality without manual handling or specialized tubes. For instance, in April 2024, Tethis S.p.A., an Italy-based biotechnology company, announced the enrollment of the first two patients in a clinical study for its See.d platform. This platform automates standardized plasma and cell sample preparation for multiomic liquid biopsy, which involves the fixation of rare circulating tumor and immune cells on nanocoated SmartBioSurface slides. Designed to maximize sample integrity and facilitate seamless analysis of cell-free DNA and circulating tumor cells from a single draw, the platform effectively supports the entire end-to-end workflow of rare biomarker specimen collection and stabilization.

Who Are The Top Market Participants Influencing The Rare Biomarkers Specimen Collection And Stabilization Market?

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Read the full rare biomarkers specimen collection and stabilization market report here:

https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Which Region Currently Holds The Largest Share Of The Rare Biomarkers Specimen Collection And Stabilization Market?

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Biomarkers Specimen Collection And Stabilization Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2026, By The Business Research Company

Blood Transfusion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Hematology Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/hematology-diagnostic-devices-and-equipment-global-market-report

Immunochemistry Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Rare Biomarkers Specimen Collection And Stabilization Market During The Forecast Period 2026–2030?

The rare biomarkers specimen collection and stabilization market size has experienced rapid growth in recent years. It is anticipated to increase from $35.29 billion in 2025 to $38.94 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. The historical expansion of this market is attributable to developments such as the growth in molecular diagnostics research, the expansion of oncology biomarker studies, the availability of plasma-based testing methods, increasing clinical trial activity, and the rising use of biobanking practices.

The rare biomarkers specimen collection and stabilization market is projected to experience substantial expansion in the coming years, anticipated to reach a valuation of $55.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. This growth during the forecast period is primarily attributable to factors such as the wider uptake of precision diagnostics, a surging need for early disease identification, the expansion of genomic and transcriptomic testing methodologies, increasing financial commitments to biomarker-driven drug development, and the growing incorporation of AI into biomarker analysis. Furthermore, key trends shaping the market over this period encompass the increasing integration of liquid biopsy collection methods, the expanded utilization of sophisticated stabilization reagents, a heightened requirement for preserving high-sensitivity biomarkers, the broadening scope of non-invasive diagnostic applications, and a reinforced emphasis on the integrity and traceability of samples.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

Which Major Factors Are Driving The Expansion Of The Rare Biomarkers Specimen Collection And Stabilization Market?

The market for rare biomarker specimen collection and stabilization is anticipated to expand due to the rising occurrence of cancer. Cancer encompasses a wide range of illnesses marked by the unrestrained proliferation and dissemination of abnormal cells. This surge in cancer cases stems from elements like environmental factors, lifestyle choices such as smoking and an unhealthy diet, and inherent genetic predispositions, collectively creating a greater demand for accurate diagnostic and monitoring instruments. The crucial function of rare biomarker specimen collection and stabilization involves ensuring the precise preservation of blood- and tissue-derived biomarkers, essential for initial diagnosis, molecular characterization, and choosing appropriate therapies in cancer treatment. For example, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, forecast more than 35 million new cancer cases by 2050. This figure signifies a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing incidence of cancer is a key factor propelling the expansion of the rare biomarker specimen collection and stabilization market.

What Market Segments Are Evaluated Within The Rare Biomarkers Specimen Collection And Stabilization Market?

The rare biomarkers specimen collection and stabilization market covered in this report is segmented –

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles

2) By Specimen: Serum Or Plasma, Other Specimens

3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications

4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA

2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow

3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

What Trends Are Affecting The Expansion Of The Rare Biomarkers Specimen Collection And Stabilization Market?

Companies operating in the rare biomarkers specimen collection and stabilization market are increasingly concentrating on developing advanced solutions, such as automated plasma and cell sample preparation, to maintain biomarker integrity and enable high-throughput multiomics. These automated pre-analytical platforms refer to technologies that standardize the processing of blood samples, including plasma separation, cell fixation, and slide preparation, directly at the point of collection, ensuring consistent specimen quality without manual handling or specialized tubes. For instance, in April 2024, Tethis S.p.A., an Italy-based biotechnology company, announced the enrollment of the first two patients in a clinical study for its See.d platform. This platform automates standardized plasma and cell sample preparation for multiomic liquid biopsy, which involves the fixation of rare circulating tumor and immune cells on nanocoated SmartBioSurface slides. Designed to maximize sample integrity and facilitate seamless analysis of cell-free DNA and circulating tumor cells from a single draw, the platform effectively supports the entire end-to-end workflow of rare biomarker specimen collection and stabilization.

Who Are The Top Market Participants Influencing The Rare Biomarkers Specimen Collection And Stabilization Market?

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Read the full rare biomarkers specimen collection and stabilization market report here:

https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Which Region Currently Holds The Largest Share Of The Rare Biomarkers Specimen Collection And Stabilization Market?

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Biomarkers Specimen Collection And Stabilization Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2026, By The Business Research Company

Blood Transfusion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Hematology Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/hematology-diagnostic-devices-and-equipment-global-market-report

Immunochemistry Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Rare Biomarkers Specimen Collection And Stabilization Market During The Forecast Period 2026–2030?

The rare biomarkers specimen collection and stabilization market size has experienced rapid growth in recent years. It is anticipated to increase from $35.29 billion in 2025 to $38.94 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. The historical expansion of this market is attributable to developments such as the growth in molecular diagnostics research, the expansion of oncology biomarker studies, the availability of plasma-based testing methods, increasing clinical trial activity, and the rising use of biobanking practices.

The rare biomarkers specimen collection and stabilization market is projected to experience substantial expansion in the coming years, anticipated to reach a valuation of $55.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. This growth during the forecast period is primarily attributable to factors such as the wider uptake of precision diagnostics, a surging need for early disease identification, the expansion of genomic and transcriptomic testing methodologies, increasing financial commitments to biomarker-driven drug development, and the growing incorporation of AI into biomarker analysis. Furthermore, key trends shaping the market over this period encompass the increasing integration of liquid biopsy collection methods, the expanded utilization of sophisticated stabilization reagents, a heightened requirement for preserving high-sensitivity biomarkers, the broadening scope of non-invasive diagnostic applications, and a reinforced emphasis on the integrity and traceability of samples.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

Which Major Factors Are Driving The Expansion Of The Rare Biomarkers Specimen Collection And Stabilization Market?

The market for rare biomarker specimen collection and stabilization is anticipated to expand due to the rising occurrence of cancer. Cancer encompasses a wide range of illnesses marked by the unrestrained proliferation and dissemination of abnormal cells. This surge in cancer cases stems from elements like environmental factors, lifestyle choices such as smoking and an unhealthy diet, and inherent genetic predispositions, collectively creating a greater demand for accurate diagnostic and monitoring instruments. The crucial function of rare biomarker specimen collection and stabilization involves ensuring the precise preservation of blood- and tissue-derived biomarkers, essential for initial diagnosis, molecular characterization, and choosing appropriate therapies in cancer treatment. For example, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, forecast more than 35 million new cancer cases by 2050. This figure signifies a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing incidence of cancer is a key factor propelling the expansion of the rare biomarker specimen collection and stabilization market.

What Market Segments Are Evaluated Within The Rare Biomarkers Specimen Collection And Stabilization Market?

The rare biomarkers specimen collection and stabilization market covered in this report is segmented –

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles

2) By Specimen: Serum Or Plasma, Other Specimens

3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications

4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users

Subsegments:

1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA

2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow

3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

What Trends Are Affecting The Expansion Of The Rare Biomarkers Specimen Collection And Stabilization Market?

Companies operating in the rare biomarkers specimen collection and stabilization market are increasingly concentrating on developing advanced solutions, such as automated plasma and cell sample preparation, to maintain biomarker integrity and enable high-throughput multiomics. These automated pre-analytical platforms refer to technologies that standardize the processing of blood samples, including plasma separation, cell fixation, and slide preparation, directly at the point of collection, ensuring consistent specimen quality without manual handling or specialized tubes. For instance, in April 2024, Tethis S.p.A., an Italy-based biotechnology company, announced the enrollment of the first two patients in a clinical study for its See.d platform. This platform automates standardized plasma and cell sample preparation for multiomic liquid biopsy, which involves the fixation of rare circulating tumor and immune cells on nanocoated SmartBioSurface slides. Designed to maximize sample integrity and facilitate seamless analysis of cell-free DNA and circulating tumor cells from a single draw, the platform effectively supports the entire end-to-end workflow of rare biomarker specimen collection and stabilization.

Who Are The Top Market Participants Influencing The Rare Biomarkers Specimen Collection And Stabilization Market?

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Read the full rare biomarkers specimen collection and stabilization market report here:

https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Which Region Currently Holds The Largest Share Of The Rare Biomarkers Specimen Collection And Stabilization Market?

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Biomarkers Specimen Collection And Stabilization Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2026, By The Business Research Company

Blood Transfusion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Hematology Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/hematology-diagnostic-devices-and-equipment-global-market-report

Immunochemistry Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model